{"groups":[{"description":"Patients receive fludarabine phosphate IV over 60 minutes on days -7 to -3 and melphalan hydrochloride IV over 20 minutes on day -2.\n\nPatients undergo PBSC HCT on day 0.\n\nPatients receive cyclophosphamide IV over 1-2 hours on days 3-4, mycophenolate mofetil IV or PO TID beginning on days 5 and stopping on day 35 if no severe GVHD is present-35, and tacrolimus IV continuously on days 5-180 with a taper beginning on day 90 in the absence of disease progression or unacceptable toxicity.\n\nCyclophosphamide: Given IV\n\nFludarabine Phosphate: Given IV\n\nHematopoietic Cell Transplantation: Undergo PBSC HCT\n\nLaboratory Biomarker Analysis: Correlative studies\n\nMelphalan Hydrochloride: Given IV\n\nMycophenolate Mofetil: Given IV or PO\n\nPeripheral Blood Stem Cell Transplantation: Undergo PBSC HCT\n\nQuality-of-Life Assessment: Ancillary studies\n\nTacrolimus: Given IV","id":"FG000","title":"Regimen A (Fludarabine, Melphalan, PBSC HCT, GVHD Prophylaxis)"},{"description":"Patients receive fludarabine phosphate IV over 1-3 hours and busulfan IV over 3 hour on days -5 to -2.\n\nPatients undergo PBSC HCT on day 0.\n\nPatients receive cyclophosphamide IV over 1-2 hours on days 3-4, mycophenolate mofetil IV or PO TID beginning on days 5 and stopping on day 35 if no severe GVHD is present-35, and tacrolimus IV continuously on days 5-180 with a taper beginning on day 90 in the absence of disease progression or unacceptable toxicity.\n\nBusulfan: Given IV\n\nCyclophosphamide: Given IV\n\nFludarabine Phosphate: Given IV\n\nHematopoietic Cell Transplantation: Undergo PBSC HCT\n\nLaboratory Biomarker Analysis: Correlative studies\n\nMycophenolate Mofetil: Given IV or PO\n\nPeripheral Blood Stem Cell Transplantation: Undergo PBSC HCT\n\nQuality-of-Life Assessment: Ancillary studies\n\nTacrolimus: Given IV","id":"FG001","title":"Regimen B (Fludarabine, Busulfan, PBSC HCT, GVHD Prophylaxis)"},{"description":"Patients receive fludarabine phosphate IV over 60 minutes on days -7 to -5 and TBI BID on days -4 to -1.\n\nPatients undergo PBSC HCT on day 0.\n\nPatients receive cyclophosphamide IV over 1-2 hours on days 3-4, mycophenolate mofetil IV or PO TID beginning on days 5 and stopping on day 35 if no severe GVHD is present-35, and tacrolimus IV continuously on days 5-180 with a taper beginning on day 90 in the absence of disease progression or unacceptable toxicity.\n\nCyclophosphamide: Given IV\n\nFludarabine Phosphate: Given IV\n\nHematopoietic Cell Transplantation: Undergo PBSC HCT\n\nLaboratory Biomarker Analysis: Correlative studies\n\nMycophenolate Mofetil: Given IV or PO\n\nPeripheral Blood Stem Cell Transplantation: Undergo PBSC HCT\n\nQuality-of-Life Assessment: Ancillary studies\n\nTacrolimus: Given IV\n\nTotal-Body Irradiation: Undergo TBI","id":"FG002","title":"Regimen C (Fludarabine, TBI, PBSC HCT, GVHD Prophylaxis)"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"19"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"19"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"19"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"19"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}